Stock Analysis on Net

Cytokinetics Inc. (NASDAQ:CYTK)

This company has been moved to the archive! The financial data has not been updated since November 3, 2023.

Analysis of Revenues 

Microsoft Excel

Revenues as Reported

Cytokinetics Inc., income statement, revenues

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Revenues 94,588 70,428 55,828 26,868 31,501

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).


Revenue Trend
The revenue demonstrated a generally increasing trend over the analyzed five-year period. Beginning at $31,501 thousand in 2018, it decreased to $26,868 thousand in 2019, marking the only year-over-year decline within the set. Subsequently, revenue experienced significant growth, reaching $55,828 thousand in 2020, which represents more than a doubling from the previous year.
The upward trajectory continued in the subsequent years, with revenues attaining $70,428 thousand in 2021 and further increasing to $94,588 thousand in 2022. This pattern indicates strong revenue expansion, particularly from 2019 through 2022, reflecting a compound annual growth rate that suggests improving market performance or increased sales activities.
Overall, the data reveals a recovery following the 2019 dip, with substantial growth in the later years, indicating a positive financial development in terms of revenue generation.